Table 2.
Time-dependent BMD and bone markers' behavior
| Parameter | Baseline | 3 months | 6 months | 12 months |
|---|---|---|---|---|
| Control (n = 44) | ||||
| Total lumbar spine BMD, g/cm2 | 0.934±0.129 | 0.922±0.135 | 0.933±0.136 | |
| Total hip BMD, g/cm2 | 0.847±0.092 | 0.847±0.095 | 0.854±0.100 | |
| P1NP, μg/L | 75.3±44.4 | 106.9±89.9 | ||
| BSAP, μg/L | 15.7±13.9 | 15.9±10.6 | ||
| β-CTX, μg/L | 0.8±0.4 | 0.6±0.4 | ||
| DPD, nmol/mmol | 8.2±2.7 | 7.2±3.5 | ||
| PTH, ng/L | 147.6±137.1 | 113.0±84.5 | ||
| Denosumab (n = 46) | ||||
| Total lumbar spine BMD, g/cm2 | 1.002±0.139 | 1.033±0.140 | 1.054±0.140 | |
| Total hip BMD, g/cm2 | 0.925±0.132 | 0.941±0.132 | 0.955±0.130 | |
| P1NP, μg/L | 66.6±51.6 | 40.8±34.8 | ||
| BSAP, μg/L | 13.5±14.8 | 8.6±7.2 | ||
| β-CTX, μg/L | 0.6±0.3 | 0.1±0.1 | ||
| DPD, nmol/mmol | 7.2±3.0 | 5.0±1.6 | ||
| PTH, ng/L | 163.2±153.5 | 167.2±173.6 |
Data are mean ± SD. PTH, parathyroid hormone; BSAP, bone-specific alkaline phosphatase; P1NP, procollagen-1 N-terminal propeptide; β-CTX, β-isomer of C-terminal telopeptide of type I collagen; DPD, urine deoxypyridinoline/Cr.